• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drug Target Insights >Preliminary in Vivo Evaluation of a Hybrid Armored Vascular Graft Combining Electrospinning and Additive Manufacturing Techniques
【24h】

Preliminary in Vivo Evaluation of a Hybrid Armored Vascular Graft Combining Electrospinning and Additive Manufacturing Techniques

机译：结合静电纺丝和增材制造技术的混合铠装血管移植物的体内初步评估

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In this study, we tested in vivo effectiveness of a previously developed poly-L-lactide/poly-8-caprolactone armored vascular graft releasing heparin. This bioprosthesis was designed in order to overcome the main drawbacks of tissue-engineered vascular grafts, mainly concerning poor mechanical properties, thrombogenicity, and endothelialization. The bioprosthesis was successfully implanted in an aortic vascular reconstruction model in rabbits. All grafts implanted were patent at four weeks postoperatively and have been adequately populated by endogenous cells without signs of thrombosis or structural failure and with no need of antiplatelet therapy. The results of this preliminary study might warrant for further larger controlled in vivo studies to further confirm these findings.
机译：在这项研究中，我们测试了先前开发的释放肝素的聚L-丙交酯/聚8-己内酯铠装血管移植物的体内有效性。设计这种生物假体是为了克服组织工程化血管移植的主要缺点，主要是有关较差的机械性能，血栓形成性和内皮化。该生物假体已成功植入兔的主动脉血管重建模型中。术后四周植入的所有移植物均已获得专利，并且已被内源性细胞充分填充，没有血栓形成或结构衰竭的迹象，并且不需要抗血小板治疗。这项初步研究的结果可能需要进行更大范围的体内对照研究，以进一步证实这些发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号